Novo Nordisk AS (NONOF)
105.00
+2.16
(+2.10%)
USD |
OTCM |
Nov 22, 16:00
Novo Nordisk Max Drawdown (5Y): 26.54% for Oct. 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2024 | 26.54% |
| September 30, 2024 | 24.80% |
| August 31, 2024 | 24.80% |
| July 31, 2024 | 24.80% |
| June 30, 2024 | 24.80% |
| May 31, 2024 | 24.80% |
| April 30, 2024 | 24.80% |
| March 31, 2024 | 24.80% |
| February 29, 2024 | 24.80% |
| January 31, 2024 | 24.80% |
| December 31, 2023 | 24.80% |
| November 30, 2023 | 24.80% |
| October 31, 2023 | 24.80% |
| September 30, 2023 | 27.40% |
| August 31, 2023 | 27.40% |
| July 31, 2023 | 27.40% |
| June 30, 2023 | 27.40% |
| May 31, 2023 | 27.40% |
| April 30, 2023 | 27.40% |
| March 31, 2023 | 27.40% |
| February 28, 2023 | 27.40% |
| January 31, 2023 | 27.40% |
| December 31, 2022 | 27.40% |
| November 30, 2022 | 27.40% |
| October 31, 2022 | 27.40% |
| Date | Value |
|---|---|
| September 30, 2022 | 27.40% |
| August 31, 2022 | 27.40% |
| July 31, 2022 | 27.40% |
| June 30, 2022 | 27.61% |
| May 31, 2022 | 27.61% |
| April 30, 2022 | 32.99% |
| March 31, 2022 | 39.19% |
| February 28, 2022 | 42.96% |
| January 31, 2022 | 42.96% |
| December 31, 2021 | 42.96% |
| November 30, 2021 | 42.96% |
| October 31, 2021 | 44.86% |
| September 30, 2021 | 44.86% |
| August 31, 2021 | 44.86% |
| July 31, 2021 | 44.86% |
| June 30, 2021 | 44.86% |
| May 31, 2021 | 44.86% |
| April 30, 2021 | 44.86% |
| March 31, 2021 | 44.86% |
| February 28, 2021 | 44.86% |
| January 31, 2021 | 44.86% |
| December 31, 2020 | 44.86% |
| November 30, 2020 | 44.86% |
| October 31, 2020 | 44.86% |
| September 30, 2020 | 44.86% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
24.80%
Minimum
Oct 2023
44.86%
Maximum
Nov 2019
35.18%
Average
30.30%
Median
Max Drawdown (5Y) Benchmarks
| Eli Lilly and Co | 22.48% |
| Genmab AS | 54.19% |
| Ascendis Pharma AS | 61.72% |
| Galecto Inc | -- |